期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Comprehensive treatment for the peritoneal metastasis from gastric cancer 被引量:1
1
作者 Yutaka Yonemura Emel Canbay +13 位作者 Yoshio Endou Haruaki Ishibashi Akiyosi Mizumoto Yan Li Yang Liu Kazuyoshi Takeshita Masumi Ichinose Nobuyuki Takao Takuya Saitou Kousuke Noguchi Masamitu Hirano Oliver Glehen Bjorn Br?cher Paul H Sugarbaker 《World Journal of Surgical Procedures》 2015年第2期187-197,共11页
Recently, a novel comprehensive treatment consisting of cytoreductive surgery(CRS) and perioperative chemotherapy(POC) was developed for the treatment of peritoneal metastasis(PM) with a curative intent. In the treatm... Recently, a novel comprehensive treatment consisting of cytoreductive surgery(CRS) and perioperative chemotherapy(POC) was developed for the treatment of peritoneal metastasis(PM) with a curative intent. In the treatment, the macroscopic disease is completely removed by the peritonectomy techniques in combination with POC. This article reviews the results of the comprehensive treatment for PM from gastric cancer, and verifies the effects of CRS and POC, including neoadjuvant chemotherapy(NAC) and hyperthermic intraoperative intraperitoneal chemotherapy(HIPEC). Completeness of cytoreduction, peritoneal carcinomatosis index(PCI) less than the threshold levels after NAC,absence of ascites, cytologic status, pathologic response after NAC are the independent prognostic factors. Among these prognostic factors, PCI threshold level is the most valuable independent prognostic factor. After staging laparoscopy, patients with PM from gastric cancer are recommended to treat with NAC before CRS. After NAC, indication for CRS is determined by laparoscopy. The indications of the comprehensive treatment are patients with PCI less than the threshold levels, negative cytology, and responders after NAC. Patients satisfy these factors are the candidates for the CRS and HIPEC. 展开更多
关键词 GASTRIC cancer Hyperthermic INTRAOPERATIVE INTRAPERITONEAL chemotherapy PERITONEAL metastasis PERITONECTOMY
下载PDF
New frontiers in peritoneal malignancies
2
作者 Emel Canbay 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第3期272-273,共2页
I was honored to be asked to write an editorial on 'cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy' (1) written by Paul H. Sugarbaker. A strategic approach usin... I was honored to be asked to write an editorial on 'cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy' (1) written by Paul H. Sugarbaker. A strategic approach using peritonectomy and cytoreductive surgery to treat peritoneal cancers has gradually evolved over the past 30 years that has emanated by our impressive leader Paul H. Sugarbaker. He has brought many surgeons together from all over the world for these procedures. His skill made so many of us enthused by peritonectomy procedures and cytoreductive surgery with long operation time, a major postoperative morbidity and high mortality risk. However, we are all persisted with these procedures because of sometimes moribund patients with peritoneal cancers may cure with peritonectomy procedures and cytoreductive surgery. 展开更多
关键词 New frontiers in peritoneal malignancies
下载PDF
5-氨基酮戊酸光动力学诊断腹膜转移癌的研究进展
3
作者 姬忠贺 刘洋 +1 位作者 Yutaka Yonemura 李雁 《首都医科大学学报》 CAS 北大核心 2018年第3期469-475,共7页
腹膜转移(peritoneal metastasis,PM)一直被视作癌症的终末阶段。20世纪90年代早期,外科肿瘤学界发展了细胞减灭术(cytoreductive surgery,CRS)加腹腔热灌注化学药物治疗(hyperthermic intraperitoneal chemotherapy,HIPEC)的综合治疗策... 腹膜转移(peritoneal metastasis,PM)一直被视作癌症的终末阶段。20世纪90年代早期,外科肿瘤学界发展了细胞减灭术(cytoreductive surgery,CRS)加腹腔热灌注化学药物治疗(hyperthermic intraperitoneal chemotherapy,HIPEC)的综合治疗策略,可延长部分经谨慎选择的PM患者生存期。细胞减灭程度(completeness of cytoreduction,CCR)是该综合治疗后最重要的独立生存预测因子。然而,现行的手术技术容易遗漏肉眼难以发现的隐匿部位PM或微小癌灶,PM仍是常规CRS术后主要的复发形式。因此,近年来,光动力学诊断(photodynamic diagnosis,PDD)方法逐渐发展,并用于检测PM。本综述旨在总结5-氨基酮戊酸(5-aminolevulinic acid,5-ALA)PDD技术在PM中的应用进展。 展开更多
关键词 氨基酮戊酸 光动力学诊断 腹膜表面恶性肿瘤 PEPT1 ABCG2 亚铁螯合酶
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部